BCD-263
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for BCD-263, covering 2025-07-08 to 2025-07-08. Get the full timeline:
Most recent: Clinical Trial Update: A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin [Phase 1]